Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Annexin A2 is increased in serous ovarian cancer and plays an essential role in ovarian cancer invasion and metastasis. In combination with S100A10, annexin A2 plays an important role in the plasminogen activator system regulating plasmin production. The aim of this study was to investigate the potential utility of all-trans retinoid acid (ATRA), an inhibitor of the annexin A2-S100A10 signalling pathway, as a new therapeutic against serous ovarian cancer. METHODS: In this study we determined the effects of ATRA treatment (1-5 μM) on annexin A2 and S100A10 expression, plasmin activation, and the ability of ATRA to inhibit serous ovarian cancer cell survival, motility and invasion in vitro. We also employed an ex vivo tissue explant assay to assess response to ATRA treatment in serous ovarian cancers. Cryopreserved serous ovarian cancer tissues were cultured on gelatin sponges for 72 h with ATRA (1 μM). Effects on apoptosis and proliferation were assessed by immunohistochemistry using antibodies to cleaved caspase 3 or Ki67, respectively. RESULTS: Survival of serous ovarian cancer cells (OVCAR-3, OV-90, & OAW28) was significantly decreased by ATRA treatment (1-5 μM). ATRA (1 μM) also significantly decreased proliferation (Ki67 positivity, p = 0.0034), S100A10 protein levels (p = 0.0273), and increased cell apoptosis (cleaved caspase-3 positivity, p = 0.0024) in serous ovarian cancer tissues using the ex vivo tissue explant assay. In OAW28 cells, reduced cell survival following ATRA treatment was associated with a reduction of S100A10 mRNA and protein levels, S100A10 and annexin A2 membrane localization, plasmin generation, motility and invasion. In contrast, ATRA inhibited OV-90 cell survival and invasion but did not affect plasmin activation or S100A10 and annexin A2 expression or membrane localization. CONCLUSIONS: These findings suggest that ATRA inhibits serous ovarian cancer proliferation and invasion via both S100A10 dependant and S100A10 independent mechanisms. Our results show that ATRA has promising potential as a novel therapy against serous ovarian cancer that warrants further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to its differentiating effect, it has also been reported to inhibit the proliferation of lymphoma and lung, liver and solid ovarian tumors [7,185,193].”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [185]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Apart from the well-known indications in hypovitaminosis and skin diseases, retinoids have been successfully used in treating cancer”
From Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity (2021) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N., & Noy, N. (2007) · Cell · doi:10.1016/j.cell.2007.02.050 · Cited by 680
Retinoids, Retinoic Acid Receptors, and Cancer
Tang, X.-H., & Gudas, L. J. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130303 · Cited by 596
The tumor microenvironment is a dominant force in multidrug resistance
Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 443
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Annexin II and Bleeding in Acute Promyelocytic Leukemia
Menell, J. S., Cesarman, G. M., Jacovina, A. T., McLaughlin, M. A., Lev, E. A., & Hajjar, K. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904013401303 · Cited by 387
Annexin A2 Heterotetramer: Structure and Function
Bharadwaj, A., Bydoun, M., Holloway, R., & Waisman, D. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14036259 · Cited by 307
Cited by
Carazo, A., Macáková, K., Matoušová, K., Krčmová, L. K., Protti, M., & Mladěnka, P. (2021) · Nutrients · doi:10.3390/nu13051703 · Cited by 461
Friend or Foe: S100 Proteins in Cancer
Allgöwer, C., Kretz, A.-L., von Karstedt, S., Wittau, M., Henne-Bruns, D., & Lemke, J. (2020) · Cancers · doi:10.3390/cancers12082037 · Cited by 131
“This leads to the production of plasmin, which results in ECM degradation, EMT, and angiogenesis [151,152].”
BackgroundBharadwaj, A. G., Holloway, R. W., Miller, V. A., & Waisman, D. M. (2021) · Cancers · doi:10.3390/cancers13081838 · Cited by 127
“Lokman et al. found that ATRA treatment resulted in downregulation of p11 and p36 mRNA and cell surface protein levels with a concomitant reduction in plasmin activity, and invasion, in the serous ovarian cancer cell line (OAW28) [183].”
BackgroundInfluentialCurrent Trends in ATRA Delivery for Cancer Therapy
Giuli, M. V., Hanieh, P. N., Giuliani, E., Rinaldi, F., Marianecci, C., Screpanti, I., Checquolo, S., & Carafa, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080707 · Cited by 100
“More recently, it has been demonstrated that ATRA inhibited proliferation and invasion in ovarian cancer [37], liver cancer [38], and lung cancer [39].”
BackgroundTargeting the retinoic acid signaling pathway as a modern precision therapy against cancers
Lavudi, K., Nuguri, S. M., Olverson, Z. A., Dhanabalan, A. K., Patnaik, S., & Kokkanti, R. R. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1254612 · Cited by 99
Metadata
- Authors
- Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C.
- Affiliations
- The University of Adelaide (AU)
- Royal Adelaide Hospital (AU)
- Adelaide University (AU)
- Corresponding author
- Ricciardelli, Carmela
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2019-01-08
- Volume
- 38
- Issue
- 1
- Pages
- 10-10
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC6325857
- OpenAlex
- W2917305526
- Cited by
- 39
- References
- 46
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 7 · 2023: 7 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 2
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Council South Australia (N/A)
- Ovarian Cancer Research Foundation (N/A)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- all-trans retinoic acid, serous ovarian cancer, annexin A2, S100A10, plasminogen activation system, plasmin activation, tumor invasion, cell motility, apoptosis, cell proliferation, cancer therapy, OVCAR-3 cells
- MeSH terms
- Antineoplastic Agents, Cell Survival, Female, Humans, Ovarian Neoplasms, Tretinoin, Cystadenocarcinoma, Serous, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. https://app.cochat.ai/papers/10.1186/s13046-018-1017-7
- The paper
- Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C. (2019). Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-018-1017-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.